| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/18/2005 | US20050182125 Therapy for neurodegenerative disorders; cardiovascular diosrders; antiproliferative agents; antiinflammatory agents; vision defects; strokes; administering a statin compound such as avorvastatin |
| 08/18/2005 | US20050182124 Ester bacteriostat for stabilizing cosmetics |
| 08/18/2005 | US20050182122 Method of treating abnormal cell growth using indolinone compounds |
| 08/18/2005 | US20050182120 Fungicides, microbiocides |
| 08/18/2005 | US20050182119 Anticancer agents; e.g. 1-(4-aminosulfonylphenyl)-3-trifluoromethyl-5-(2,5-dimethylphenyl)-4,5-dihydropyrazole or 1-(4-aminosulfonylphenyl)-3-trifluoromethyl-5-[3,5-di(trifluoromethyl)phenyl]-4,5-dihydropyrazole; improved antitumor activity; colon cancer, bowel cancer, or prostate cancer |
| 08/18/2005 | US20050182118 Amidine derivatives for treating amyloidosis |
| 08/18/2005 | US20050182116 Such as 5-amino-3-[[4-(aminosulfonyl)phenyl]amino]-N-(2,6-difluorophenyl)-1H-1,2,4-triazole-1-carbothioamide, used as cyclin dependent and tyrosine kinase inhibitors, for prophylaxis of tumors |
| 08/18/2005 | US20050182115 Agent for preventing and/or treating sinusitis |
| 08/18/2005 | US20050182113 Method for preparing diaryl-substituted isoxazole compounds |
| 08/18/2005 | US20050182112 3-[4-(3,6-dihydro-2H-thiopyran-4-yl) phenyl]-]5[1H or 2H-1,2,3-triazol-1 or 2-yl] oxazolidin-2-ones; grampositive bactericides for drug resistant bacteria, especially Staphylococcus, Enterococcus, and Streptococcus |
| 08/18/2005 | US20050182110 tetracylic bridged ring compounds such as 9-nitro-11-amino-11-((imidazol-2-yl)aminocarbonyl)-9,10-dihydro-9,10-ethanoanthracene; treating obesity, diabetes and inflammatory or immune associated diseases; nuclear factor kappa beta (NF-KB) |
| 08/18/2005 | US20050182109 Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase |
| 08/18/2005 | US20050182108 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants |
| 08/18/2005 | US20050182106 Medicinal composition for mitigating blood lipid or lowering blood homocysteine |
| 08/18/2005 | US20050182105 Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
| 08/18/2005 | US20050182104 E.g., Methyl 2-[2-[2-(3,5-difluorophenyl)acetyl-amino]propanoylamino]-5-propylthiazole-4-carboxylate; beta -amyloid peptide inhibitors; used to treat senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy and/or cerebrovascular disorders |
| 08/18/2005 | US20050182103 Substituted 2,3-diphenyl pyridines |
| 08/18/2005 | US20050182101 Prodrugs of proton pump inhibitors |
| 08/18/2005 | US20050182100 Method of use |
| 08/18/2005 | US20050182099 Alkylammonium salts of omepazole and esomeprazole |
| 08/18/2005 | US20050182098 Administering taxanes having a carbamoyloxy substituent at C(10), a hydroxy substituent at C(7), and a range of C(2), C(9), C(14), and side chain substitutions for inhibiting tumor growth |
| 08/18/2005 | US20050182097 Amyotrophic Lateral Sclerosis; Parkinson's disease; Alzheimer's disease |
| 08/18/2005 | US20050182095 Piperdine derivatives useful as CCR3 antagonists |
| 08/18/2005 | US20050182094 N-[[4-(2-Chloro-4-fluorophenoxy)[1,4'-bipiperidin]-1'-yl]carbonyl]-4-methyl benzenesulfonamide, used for prophylaxis of respiratory system disorders or as antiallergens |
| 08/18/2005 | US20050182093 Novel compounds |
| 08/18/2005 | US20050182090 1R,2R,3S)-2-(3-(2-Thienyl)-1,2,4-oxadiazol-5-yl)-3-(4-chlorophenyl)-tropane; amisulpride, amisulpride, bromocriptine, buspirone, cabergoline, docarpamine, dopexamine, etilevodopa, fenoldopam, ibopamine, lisuride, nolomirole, pergolide, piripedil, pramipexole, quinagolide, quinelorane; Alzheimer's disease |
| 08/18/2005 | US20050182089 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist |
| 08/18/2005 | US20050182088 Modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine; thio-bridged aryl derivatives; treats central and autonomic nervous system disorders |
| 08/18/2005 | US20050182087 antidiabetic agents; type 2 diabetes; e.g. 1-Ethyl-6-(1-ethynylcyclohexylamino)-7-methyl-4-oxo-1,4-dihydro-(1,8)naphthyridine-3-carboxylate |
| 08/18/2005 | US20050182086 Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| 08/18/2005 | US20050182085 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| 08/18/2005 | US20050182084 Method for treating erectile dysfunction |
| 08/18/2005 | US20050182083 Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof |
| 08/18/2005 | US20050182082 Modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof |
| 08/18/2005 | US20050182081 Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents |
| 08/18/2005 | US20050182080 Therapeutic compounds |
| 08/18/2005 | US20050182078 inhibitors of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4); antiproliferative agents; cancer, endometriosis, postsurgical vascular stenosis and restenosis |
| 08/18/2005 | US20050182077 8-amino-7-substituted-2,6-dioxo-1,2,3,6-tetrahydro-7H-purines; erectile dysfunction; sexual disorders; psychological disorders; hypotensive agents; restenosis; cardiovascular disorders; antidiabetic agents; vision defects; autoimmune diseases; anticancer agents |
| 08/18/2005 | US20050182076 Transdermal penetration system and treatment for cellulite |
| 08/18/2005 | US20050182075 For prophylaxis and therapy of hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, an immunosuppressant |
| 08/18/2005 | US20050182074 fluconazole as cytochrome P-450 isoenzyme CYP2C17 inhibitor; dosage form; separate containers containing fluconazole and voriconazole |
| 08/18/2005 | US20050182071 Methods and systems for inhibiting arrhythmia |
| 08/18/2005 | US20050182070 Method for the treatment of allergic conditions |
| 08/18/2005 | US20050182069 For treatment of asthma, allergies, inflammation and anxiety; antihistamines; sedatives; tranquilizing agents; 2[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetamide |
| 08/18/2005 | US20050182068 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 08/18/2005 | US20050182067 Vanilloid receptor ligands and their use in treatments |
| 08/18/2005 | US20050182066 Methods for the production of sildenafil base and citrate salt |
| 08/18/2005 | US20050182065 use of (3S,4R)-3,4-dihydro-4-(2,3 -dihydro-2-methyl-3-oxopyridazin-6-yl)oxy-3-hydroxy-6-(3 -hydroxyphenyl)sulphonyl-2,2,3-trimethyl-2H-benzo[b]pyran to treat alopecia |
| 08/18/2005 | US20050182064 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| 08/18/2005 | US20050182063 Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands |
| 08/18/2005 | US20050182062 1,4-Diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof |
| 08/18/2005 | US20050182061 Phthalimide compounds useful as protein kinase inhibitors |
| 08/18/2005 | US20050182060 2-Substituted and 4-substituted aryl nitrone compounds |
| 08/18/2005 | US20050182059 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives |
| 08/18/2005 | US20050182058 Anticancer agents; inhibits tyrosine kinase activity of growth factor receptors; antiproliferative agents |
| 08/18/2005 | US20050182057 Aryl N-cyanoguanidines and methods related thereto |
| 08/18/2005 | US20050182056 Modified release formulations of at least one form of tramadol |
| 08/18/2005 | US20050182054 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 08/18/2005 | US20050182053 3-amino-6-{4-[2-hydroxy-2-(substituted heteroaryl)ethylamino]-piperidin-1-yl}thieno[2,3-b]pyridine-2-carboxylic acid amides; reductive amination; I kappa B kinase inhibitors; autoimmune diseases; antiinflammatory and anticarcinogenic agents |
| 08/18/2005 | US20050182050 Therapeutic heterocyclic compounds |
| 08/18/2005 | US20050182049 Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists |
| 08/18/2005 | US20050182047 Treatment of demyelinating disorders |
| 08/18/2005 | US20050182046 Alzheimer's disease; 3-(S)-(N'-(3,5-difluorophenylacetyl)-L-alaninyl)amino-1-benzyl- epsilon -caprolactam; 4-(N'-(3,5-Difluorophenylacetyl)-L-alaninyl)amino-1-(pyrid-4-yl)-71,2,3,4-tetrahydroisoquinolin-3-one |
| 08/18/2005 | US20050182045 Fused ring 4-oxopyrimidine derivative |
| 08/18/2005 | US20050182044 donepezil, rivastigmine, metrifonate, physostigmine, eptastigmine, galantamine, and huperzine A with beta-amyloid peptide inhibitor phenserine, tolserine, N1-benzylnorphysostigmine, N1-benzylnorphenserine, N1benzylnortolserine, N1-benzylnorcymserine, Alzheimer's disease |
| 08/18/2005 | US20050182042 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/18/2005 | US20050182041 N-Benzoylazetidines, e.g., N-(3,5-di-tert-butyl-4-hydroxybenzoyl)-3-hydroxyazetidine; cyclooxygenase-1 and/or cyclooxygenase-2 inhibitors; treating inflammatory diseases including various kinds of arthritis, lupus, dysmenorrhea, ankylosing spondylitis, edema, migraines, and aplastic anemia |
| 08/18/2005 | US20050182040 Benzamide derivatives |
| 08/18/2005 | US20050182039 Use of Loteprednol etabonate for the treatment of dry eye |
| 08/18/2005 | US20050182038 Selective estrogen receptor modulators |
| 08/18/2005 | US20050182037 Beta-sitosterol; fatty acid complexes; antioxidants; colds, flu, diabetes, allergies, asthma, pneumonia, fibromyalgia, HIV infection, hepatitis C infection, urinary flow, pelvic inflammatory disease and multiple sclerosis; nutritional supplements |
| 08/18/2005 | US20050182036 Medicinal composition containing an HMG-CoA reductase inhibitor |
| 08/18/2005 | US20050182035 cyclohexane ring is 3,5-dihydroxy-substituted and 2,4-alkylene-bridged; treating metabolic bone disease, cancer, skin disorders, immune system disorders, asthma, hypertension, hypothyroidism, hypocalcemia, female infertility and alopecia |
| 08/18/2005 | US20050182034 Method of locking 1alpha-OH of vitamin D compounds in axial orientation |
| 08/18/2005 | US20050182033 eczema, hypercalcemia, hyperparathyroidism, sarcoidosis, or vitamin D intoxication |
| 08/18/2005 | US20050182032 vitamin D3 antagonist activity; treating Paget's disease, bone diseases, hypercalcemia or osteoporosis; e.g. 1 alpha,25-dihydroxyvitamin D3-26 23-lactam, N-(p-methoxy)benzyl |
| 08/18/2005 | US20050182031 Florfenicol prodrug having improved water solubility |
| 08/18/2005 | US20050182030 Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution |
| 08/18/2005 | US20050182029 Metformin tocopherol phosphate gel; time-release agent; antihyperglycemic agent; improved gastrointestinal absorption |
| 08/18/2005 | US20050182028 bisphosphonates ( alendronate sodium) as anionic substances could potentially be carried by a cation-bearing aminoalkyl methacrylate copolymer a cation-bearing polymer resulting in a conjugate with a better in vivo absorption |
| 08/18/2005 | US20050182026 Dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC) as surface active phosphotidyls; phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, or chlorestyl palmitate as spreading agent |
| 08/18/2005 | US20050182024 Estrogen complexes for ovulation inhibition; storage stability; 85% w/w in relation to the initial content of said estrogen after storage for 12 months at 40 degrees C. and 75% relative humidity |
| 08/18/2005 | US20050182023 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process |
| 08/18/2005 | US20050182022 Chondroprotective/restorative compositions and methods of use thereof |
| 08/18/2005 | US20050182021 Polysaccharide alcohol antiseptic gel |
| 08/18/2005 | US20050182020 Decreasing sterol regulatory element binding-proteins (SREBPs) which inhibits de novo synthesis of ceramide in the cell |
| 08/18/2005 | US20050182019 Phosphonate compounds |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182014 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation |
| 08/18/2005 | US20050182011 Use inhibitors of Transient Receptor Potential (TRP) channels to block non-voltage gated calcium flux into cells |
| 08/18/2005 | US20050182008 chemically synthesized double stranded siNA; NOGO genes encode potent inhibitors of neurite outgrowth; treating various nervous system disorders such as brain or spinal cord injury, cerebrovascular disorders, Alzheimer's disease, dementia, and neurodegenerative disorders |
| 08/18/2005 | US20050182002 Killing Burkitt's lymphoma cell or a chronic lymphocytic leukaemia cell |
| 08/18/2005 | US20050182001 Having immunomodulatory activity; for therapy and prophylaxis of infections caused by adenovirus, cytomegalovirus, hepatitis A virus (HAV), hepatitis B virus (HBV), flaviviruses including Yellow Fever virus, herpes virus |
| 08/18/2005 | US20050181999 Comprising a biologically active agent (e.g., antifungal) , urea and an acid (lactic acid) or ethoxydiglycol; provide better bioavailability of the active agent within the nail |
| 08/18/2005 | US20050181980 Administering a formulation comprising an effective amount of:a sulfonylurea receptor 1 (SUR1) antagonist that reduces the activity of a NCCa-ATP channel; a pharmaceutically acceptable carrier |
| 08/18/2005 | US20050181974 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| 08/18/2005 | US20050181516 Bioequivalence determination using expression profiling |
| 08/18/2005 | US20050181506 Chromosome-based platforms |
| 08/18/2005 | US20050181418 Using nuclear protein (AM-1) as screening tool in diagnosing metastatic cancer |
| 08/18/2005 | US20050181416 N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use |